Nanoform Finland PLC (fra:4YL) Share Price

Company Profile

Business description
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
Contact
Cultivator II, Viikinkaari 4
Helsinki00790
FIN
T: +358 293700150
https://www.nanoform.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
108

Recommended

Strong demand for AI infrastructure drives fair value lift.

Roy Van Keulen | 30 September 2026

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,969.20	82.60	0.93%
CAC 40	7,964.51	71.36	-0.89%
DAX 40	25,199.19	200.02	-0.79%
Dow JONES (US)	50,906.05	443.87	-0.86%
FTSE 100	10,606.00	30.71	-0.29%
HKSE	24,613.27	89.70	0.37%
NASDAQ	26,861.06	63.52	0.24%
Nikkei 225	66,753.72	1,272.45	1.94%
NZX 50 Index	13,834.39	150.76	1.10%
S&P 500	7,651.54	19.30	-0.25%
S&P/ASX 200	8,789.30	80.00	0.92%
SSE Composite Index	3,842.19	11.74	0.31%